



# Remote C–H bond functionalization of androstane C-ring: C12-amination

Shuji Yamashita<sup>a,\*</sup>, Masafumi Himuro<sup>a</sup>, Yujiro Hayashi<sup>a</sup>, Masahiro Hiramatsu<sup>a,b</sup>

<sup>a</sup> Department of Chemistry, Graduate School of Science, Tohoku University, Sendai 980-8578, Japan

<sup>b</sup> Research and Analytical Center for Giant Molecules, Graduate School of Science, Tohoku University, Sendai 980-8578, Japan

## ARTICLE INFO

### Article history:

Received 6 December 2012

Revised 21 December 2012

Accepted 26 December 2012

Available online 3 January 2013

### Keywords:

C–H bond functionalization

Steroid

Androstane

Amination

## ABSTRACT

A new functionalization method for the C-ring of the androstane framework has been established. The key feature is a remote C–H amination, which enables the preparation of the C12-amino, oxo, hydroxy, and C11,12-dehydro derivatives of epiandrosterone.

© 2013 Elsevier Ltd. All rights reserved.

Chemical derivatization of steroids is an effective tool for natural product synthesis<sup>1</sup> and can provide important bioactive agents.<sup>2,3</sup> However, only a few functionalizations of the non-activated C-ring of the androstanes have been reported. In 2003, Shöneck and co-workers developed a copper-mediated remote hydroxylation of the C12 position.<sup>4–6</sup> This method enabled Gianni and Shair to accomplish the elegant total syntheses of cycloamine<sup>7</sup> and cephalostatin,<sup>8</sup> respectively. We describe here a new method to functionalize the androstane C-ring through a remote C–H amination.


Functionalization of the C-ring was investigated using epiandrosterone (**1**, Scheme 1). Protection of the secondary alcohol of **1**, stereoselective reduction of the ketone, and subsequent treatment with chlorosulfonyl isocyanate and formic acid<sup>9</sup> afforded sulfamate **2** in 80% overall yield. Rhodium-catalyzed C–H bond amination of **2** according to the Du Bois method<sup>10</sup> successfully provided the C12,17-oxathiazinane **3** in 86% yield. It is noteworthy that the C16- and C18-aminated products were not detected. This exclusive chemoselectivity is attributed to the long S–O and S–N bonds and the obtuse N–S–O angle of the sulfamate, as well as the difference in reactivity between the primary and secondary C–H bonds.<sup>10</sup> The structure of **3** was unambiguously confirmed by X-ray crystallographic analysis of the corresponding alcohol **4** (Fig. 1).<sup>11</sup>

We next examined the cleavage of the S–O and/or S–N bonds of oxathiazinane **3** (Table 1).<sup>12</sup> Birch reduction resulted in no reaction and the starting material was recovered (entry 1). Treatment of **3** with LiAlH<sub>4</sub> in THF afforded no products (entry 2),<sup>13</sup> whereas

LiAlH<sub>4</sub> reduction in toluene followed by Boc-protection furnished carbamate **5** in 39% yield (entry 3). After careful screening of reagents and conditions, we found that refluxing with AlH<sub>3</sub> in toluene afforded amino alcohol **6** in 90% yield (entry 5).

Selective oxidation of the amino group was achieved by treatment of **6** with 3,5-di-*t*-butyl-1,2-benzoquinone **7** to give ketone **8** in 95% yield (Scheme 2).<sup>14</sup> Stereoselective reduction of ketone **8** was realized by treatment with sodium metal in the presence of isopropanol to give the C12β-hydroxy product **9** (77%). The C11,12-dehydro derivative **10** was also prepared under Shapiro's conditions in 63% overall yield.



In summary, we established a versatile method to install functionality to the non-activated C-ring of epiandrosterone.




Scheme 1. Remote amination of epiandrosterone C-ring.

\* Corresponding author.

E-mail address: [s-yamashita@m.tohoku.ac.jp](mailto:s-yamashita@m.tohoku.ac.jp) (S. Yamashita).

Figure 1. ORTEP drawing of **4**.Table 1  
Cleavage of oxathiazinane moiety

| Entry | Conditions                                                                   | Results                          |
|-------|------------------------------------------------------------------------------|----------------------------------|
| 1     | Na, EtOH, NH <sub>3</sub><br>–78 to –33 °C, 2 h                              | No reaction                      |
| 2     | LiAlH <sub>4</sub> , THF, reflux, 12 h                                       | No reaction                      |
| 3     | LiAlH <sub>4</sub> , toluene, reflux, 24 h;<br>(Boc) <sub>2</sub> O, rt, 1 h | <b>5</b> : 39%<br><b>3</b> : 25% |
| 4     | Red-Al, toluene, reflux, 24 h;<br>(Boc) <sub>2</sub> O, rt, 1 h              | <b>5</b> : 53%                   |
| 5     | AlH <sub>3</sub> , toluene, reflux, 5 h                                      | <b>6</b> : 90%                   |



Scheme 2. Functionalization of the C-ring.

Rhodium-catalyzed remote C–H amination efficiently furnished the oxathiazinane, which was converted into the C12-amino, oxo, hydroxy, and C11,12-dehydro androstanes. Natural product syntheses using this strategy will be reported in due course.

## Acknowledgments

This work was supported financially by a Grant-in-Aid for Scientific Research (B) and (C) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan and the Suntory

Foundation for Life Sciences. A fellowship to M. Himuro from JSPS is gratefully acknowledged. We are grateful to Dr. S. Ishida at the Graduate School of Science, Tohoku University for his assistance with X-ray crystallographic analysis and helpful discussions.

## Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.tetlet.2012.12.103>.

## References and notes

- For selected examples of natural product synthesis from commercially available steroids, see: (a) cortistatin: Shenvi, R. A.; Guerrero, C. A.; Shi, J.; Li, C.-C.; Baran, P. S. *J. Am. Chem. Soc.* **2008**, *130*, 7241; (b) Shi, J.; Manolikakes, G.; Yeh, C.-H.; Guerrero, C. A.; Shenvi, R. A.; Shigehisa, H.; Baran, P. S. *J. Am. Chem. Soc.* **2011**, *133*, 8014; (c) sominone: Matsuya, Y.; Yamakawa, Y.; Tohda, C.; Teshigawara, K.; Yamada, M.; Nemoto, H. *Org. Lett.* **2009**, *11*, 3970; (d) pavoninin-4: Williams, J. R.; Gong, H.; Hoff, N.; Olubodun, O. I. *J. Org. Chem.* **2005**, *70*, 10732.
- Currently, many steroid-based medicines are provided by pharmaceutical companies via semi-synthesis, see: McGrath, N. A.; Brichacek, M.; Njardarson, J. T. *J. Chem. Educ.* **2010**, *87*, 1348.
- (a) Hamiton, N. M.; Dawson, M.; Fairweather, E. E.; Hamilton, N. S.; Hitchin, J. R.; James, D. I.; Jones, S. D.; Jordan, A. M.; Lyons, A. J.; Small, H. F.; Thomson, G. J.; Waddell, I. D.; Ogilvie, D. J. *J. Med. Chem.* **2012**, *55*, 4431; (b) Kranz, D. P.; Chiha, S.; zu Greffen, A. M.; Neudörfl, J.-M.; Schmalz, H.-G. *Org. Lett.* **2012**, *14*, 3692; (c) Pettit, G. R.; Moser, B. R.; Mendonça, R. F.; Knight, J. C.; Hogan, F. J. *Nat. Prod.* **2012**, *75*, 1063; (d) Farhane, S.; Fournier, M.-A.; Maltais, R.; Poirier, D. *Tetrahedron* **2011**, *67*, 2434; (e) Ravindar, K.; Reddy, M. S.; Lindqvist, L.; Pelletier, J.; Deslongchamps, P. *J. Org. Chem.* **2011**, *76*, 1269; (f) Li, Y.; Huang, J.; Liu, J.; Yan, P.; Liu, H.; Sun, Q.; Wang, X.; Wang, C. *Steroids* **2011**, *76*, 1615; For a recent review, see: (g) Hanson, J. R. *Nat. Prod. Rep.* **2010**, *27*, 887.
- (a) Schönecker, B.; Zheldakova, T.; Liu, Y.; Köteritzsch, M.; Günther, W.; Görls, H. *Angew. Chem.* **2003**, *115*, 3361. *Angew. Chem., Int. Ed.* **2003**, *42*, 3240; (b) Schönecker, B.; Zheldakova, T.; Lange, C.; Günther, W.; Görls, H.; Bohl, M. *Chem. Eur. J.* **2004**, *10*, 6029; (c) Schönecker, B.; Lange, C.; Zheldakova, T.; Günther, W.; Görls, H.; Vaughan, G. *Tetrahedron* **2005**, *61*, 103.
- For pioneering studies on remote hydroxylation of steroids, see: (a) Groves, J. T.; Neumann, R. J. *Org. Chem.* **1988**, *53*, 3891; (b) Groves, J. T.; Neumann, R. J. *Am. Chem. Soc.* **1989**, *111*, 2900; (c) Grieco, P. A.; Stuk, T. L. *J. Am. Chem. Soc.* **1990**, *112*, 7799; (d) Stuk, T. L.; Grieco, P. A.; Marsh, M. M. *J. Org. Chem.* **1991**, *56*, 2957; (e) Kaufman, M. D.; Grieco, P. A.; Bougie, D. W. *J. Am. Chem. Soc.* **1993**, *115*, 11648; (f) Breslow, R.; Huang, Y.; Zhang, X.; Yang, J. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, *94*, 11156; (g) Breslow, R.; Gabriele, B.; Yang, J. *Tetrahedron Lett.* **1998**, *39*, 2887; (h) Yang, J.; Breslow, R. *Angew. Chem.* **2000**, *112*, 2804. *Angew. Chem., Int. Ed.* **2000**, *39*, 2692; (i) Yang, J.; Gabriele, B.; Belvedere, S.; Huang, Y.; Breslow, R. *J. Org. Chem.* **2002**, *67*, 5057.
- For recent reviews on C–H functionalization in natural product synthesis, see: (a) McMurray, L.; O'Hara, F.; Gaunt, M. J. *Chem. Soc. Rev.* **2011**, *40*, 1885; (b) Gutekunst, W. R.; Baran, P. S. *Chem. Soc. Rev.* **2011**, *40*, 1976; (c) Yamaguchi, J.; Yamaguchi, A. D.; Itami, K. *Angew. Chem.* **2012**, *124*, 9092. *Angew. Chem., Int. Ed.* **2012**, *51*, 8960.
- Giannis, A.; Heretsch, P.; Sarli, V.; Stöbel, A. *Angew. Chem.* **2009**, *121*, 8052. *Angew. Chem., Int. Ed.* **2009**, *48*, 7911.
- Fortner, K. C.; Kato, D.; Tanaka, Y.; Shair, M. D. *J. Am. Chem. Soc.* **2010**, *132*, 275.
- Okada, M.; Iwashita, S.; Koizumi, N. *Tetrahedron Lett.* **2000**, *41*, 7047.
- (a) Espino, C. G.; Wehn, P. M.; Chow, J.; Du Bois, J. J. *Am. Chem. Soc.* **2001**, *123*, 6935; (b) Fiori, K. W.; Espino, C. G.; Brodsky, B. H.; Du Bois, J. *Tetrahedron* **2009**, *65*, 3042.
- Crystallographic data of **4** have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC-912944. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +44 (0) 1223 336033 or e-mail: deposit@ccdc.cam.ac.uk).
- Cleavage of the oxathiazinane-ring under the reported conditions was unsuccessful. For representative conditions, see: (a) Vargas, L. M.; Roza, W.; Kouznetsov, V. *Heterocycles* **2000**, *53*, 785; (b) Wehn, P. M.; Du Bois, J. J. *Am. Chem. Soc.* **2002**, *124*, 12950; (c) Posakony, J. J.; Tewson, T. J. *Synthesis* **2002**, 859; (d) Fleming, J. J.; Fiori, K. W.; Du Bois, J. J. *Am. Chem. Soc.* **2003**, *125*, 2028; (e) Liu, Y.; Xiao, W.; Wong, M.-K.; Che, C.-M. *Org. Lett.* **2007**, *9*, 4107; (f) Airiau, E.; Girard, N.; Pizzetti, M.; Salvadori, J.; Taddei, M.; Mann, A. J. *Org. Chem.* **2010**, *75*, 8670. and Ref. 10. Treatment with oxidants [e.g., KMnO<sub>7</sub>, CrO<sub>3</sub>, IBX, (COCl)<sub>2</sub>/DMSO, TPAP/NMO, silver picolinate, and Mukaiyama reagent] did not realize the ring-opening of oxathiazinane.
- Wang, Y.-Q.; Yu, C.-B.; Wang, D.-W.; Wang, X.-B.; Zhou, Y.-G. *Org. Lett.* **2008**, *10*, 2071.
- (a) Corey, E. J.; Achiwa, K. *J. Am. Chem. Soc.* **1969**, *91*, 1429; (b) Klein, R. F. X.; Bargas, L. M.; Horak, V. J. *Org. Chem.* **1988**, *53*, 5994.